References
- Chen, M. L., Patnaik, R., Hauck, W. W., Schuirmann, D. F., Hyslop, T., Williams, R. (2000). An individual bioequivalence criterion: Regulatory considerations. Statistics in Medicine 19:2821–2842.
- Chow, S. C. (1999). Individual bioequivalence: A review of FDA draft guidance. Drug Information Journal 33:435–444.
- Chow, S. C. (2013). Design and Analysis of Biosimilar Studies. New York, NY: Chapman Hall/CRC Press, Taylor & Francis.
- Chow, S. C., Liu, J. P. (2008). Design and Analysis of Bioavailability and Bioequivalence Studies – Revised and Expanded, 3rd ed. New York, NY: Taylor & Francis.
- Chow, S. C., Shao, J., Wang, H. (2008). Sample Size Calculation in Clinical Research. 2nd ed. New York, NY: Taylor & Francis.
- Chow, S. C., Song, F. Y., Chen, M. (2016). Some thoughts on drug interchangeability. Journal of Biopharmaceutical Statistics 26:178–186.
- Chow, S. C., Xu, H., Endrenyi, L., Song, F. Y. (2015). A new scaled criterion for drug interchangeability. Chinese Journal of Pharmaceutical Analysis 35(5):844–848.
- FDA. (2003a). Guidance on bioavailability and bioequivalence studies for orally administrated drug products: General considerations. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
- FDA. (2003b). Guidance on Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action, Center for Drug Evaluation and Research, the US Food and Drug Administration, Rockville, MD, USA, 2003.
- Haidar, S. H., Davit, B., Chen, M. L., Conner, D., Lee, L., Li, Q. H., Lionberger, R., Makhlouf, F., Patel, D., Schuirmann, D. J., Yu, L. X. (2008). Bioequivalence approaches for highly variable drugs and drug products. Pharmaceutical Research 25:237–241.
- WHO. (2015). World Health Organization Draft Revision on Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability, WHO Technical Report Series, No. 992, Geneva, Switzerland, 2015.